Representative Partner, Edogawa Certified Public Accountant Office

1997　Joined Showa Ota & Co. (current name: Ernst & Young ShinNihon LLC)
2010　Partner, Ernst & Young ShinNihon LLC
2019　Representative Partner, Edogawa Certified Public Accountant Office
While at an audit firm, he helped many startups, including life science and IT-related companies, go public. He currently focuses on supporting technology-related companies and is involved in a number of innovation-related policies of central ministries and agencies as an external committee member.

He has more than 10 years of experience in the medical device and drug development field, including four and a half years at a regulatory agency (PMDA).
He was engaged in medical affairs for the launch of existing and new drugs at a foreign-owned pharmaceutical company in Japan, and in the development of biopharmaceuticals at a U.S. subsidiary of a domestic pharmaceutical company.
He is the first MD with industry experience to join the Pharmaceuticals and Medical Devices Agency (PMDA), where he served as a medical reviewer in the field of medical devices and pharmaceuticals, and after leaving PMDA, he has been engaged in clinical development consulting in addition to running a medical practice and visiting nursing business.
He has extensive clinical experience in aesthetic dermatology, cosmetic surgery, obstetrics and gynecology, internal medicine, pediatrics, neurosurgery, and anesthesiology, as well as knowledge of both industry and regulatory agencies, pharmaceuticals and medical devices.

She worked at Terumo Corporation as a Research manager.
After graduating from the Graduate School of Science at a national university, she worked for 17 years in medical device development at Terumo Corporation, where she developed blood-related products, implantable medical devices for surgery, hospital products, electronic devices, and pharmaceuticals, as well as regulatory applications.
In addition, as head of the development division, she is responsible for the management of the entire development division with developing human resources. Along the way, she was seconded to the University of Tokyo Hospital for one year to conduct basic research such as cell culture with doctors and nurses and to explore needs in the medical field.
In 2015, she founded Medical Lab Partners Corporation to develop products that meet the needs of patients, and has consulted with more than 150 medical device development companies on development issues.

After graduating from Kyushu University with a degree in genetic resources engineering, he worked at Astellas Pharma, where he was involved in intellectual property matters, and was assigned to the U.S., where he was responsible for M&A and alliances.
In intellectual property litigation, he has won 12 victories and lost none, generating profits of more than 10 billion yen, by leveraging his outstanding pharmaceutical legal and intellectual property strategies. He has also co-founded several startups and served as a director and chief legal officer.
He has also served as a mentor for the Tokyo Metropolitan Government’s “Blockbuster TOKYO,” a program to support the development of drug discovery and medical ventures. Specially Appointed Professor of OI Strategy Organization, Tohoku University.

He has been in charge of medical device review at PMDA for four and a half years and has a wide range of evaluation experience from clinical trials to in-vitro studies.
He has also been a lecturer in new employee education and medical device regulatory seminars. Later, he was seconded to the Ministry of Health, Labour and Welfare, where he was responsible for the pricing of medical devices, in vitro diagnostics, regenerative medicine and other products. After leaving the government, he worked for a medical IT venture as an insurance agent for a medical device application and as a product development strategist for a major medical device manufacturer.
At Tokyo Jikei University of Medicine, where he is currently working, he conducts research on medical IT and medical devices, while also fostering venture companies and providing advice to medical device manufacturers.

Founder, Japan Biodesign Association and Adviser, Japan Biodesign Academic Society
Ex Chairman, Terumo Corporation and Ex Chairman, Japanese Association of Medical Device Industry Federation
CEO, Art Management Shimanami LLC

Former Executive Vice President, Kobayashi Pharmaceutical Co.
He was formerly the Executive Vice President of Kobayashi Pharmaceutical Co., Ltd. and the Representative Director of its affiliated company, Medicon Inc.
He has been involved in the management and development of medical device manufacturing & sales companies in Japan and in the United States over 40 years.
He is still supporting activities in management and developing new products in Medical market. He feels that the experience of working in the silicon valley in the 1990s is still useful and well today.

MBA from the University of Chicago.
Although he has been in the medtech field for the longest time, he has hands-on experience in the steel, wine, and software industries, in sales, organizational development, investment, and fundraising, and in foreign, domestic, large corporate, and venture businesses.

Caleb has started 6 businesses across diverse sectors including the entertainment, restaurant, drone and biotech industries. Together with six others, he cofounded G4S Capital and Ikigai Accelerator a venture capital and life science business Accelerator focused on connecting the Japanese and Silicon Valley entrepreneurial ecosystems.
His first interactions with life sciences in Japan was doing experiments at SPring-8 during his graduate studies. After leaving Stanford with his PhD, he founded Bell Biosystems, Inc. a synthetic biology company developing enabling tools for tracking and controlling cell therapies, where he served as CEO till early 2017.
Caleb received a B.S. Degree in Biochemistry and Molecular Biology from the Pennsylvania State University, a Ph.D. in Biophysical Chemistry from Stanford University and business training in Stanford Graduate School of Business’ Ignite Program.

Devang is a biopharma executive, scientist, and patent and corporate attorney. As the Vice President of Intellectual Property and Legal of a preclinical therapeutic mRNA startup, he is building the IP portfolio for an innovative cellular rejuvenation technology. Through a boutique consultancy, he also provides part-time non-legal scientific, strategic, and business advisory to select companies and organizations. Devang was previously a primary examiner for pharmaceutical patents at the US Patent and Trademark Office. Before that, he developed nucleic acid medicine, regenerative medicine, and biomaterials technologies as a researcher at Harvard Medical School, Kyoto University, and UCLA. He received his PhD and MS in Biomedical Engineering, as well as BS in Mathematics/Applied Science and Psychobiology, from UCLA. He received his JD, with High Tech Law Certificate with corporate specialization and honors, from Santa Clara University.

After serving as a Head of Biology in Novartis Tsukuba Research Institute（Tsukuba Lab.） and Pfizer Central Research institute　（Nagoya Lab.）, co-founded RaQualia Pharma Inc as a spin-off from Pfizer in 2008, in 2015 establish AskAt Inc. as co-founder and also Medicinal Creation Advisor as a personal company. Joined Tsubota Laboratory Inc. as an external Director in 2020. Professor of Graduate School of Medicine, Chiba University.

After the graduate school of pharmacy of Kyoto University, joined Mitsubishi Tanabe Pharmaceuticals and engaged in drug discovery research such as pharmacokinetics, pharmaceuticals, and DDS, as well as alliance-related work in the research planning department. Also engaged the application of Remicade, the first antibody drug in Japan. After earning PhD and MBA, joined to Takeda Pharmaceutical and engaged in the creation of new businesses, regenerative medicine, and hunting new technologies such as gene and cell therapy. In regenerative medicine, participated in T-CiRA, the joint research project between the CiRA (iPS Cell Research Institute of Kyoto University) and Takeda Pharmaceuticals. Based on these experiences and networks, trying to propose comprehensive support services from research, finding an appropriate partner to alliance management from the point of view of the practical experience of pharmaceutical company side. My hobbies are yachting and astronomical observation.

After studying materials engineering at The University of Tokyo, Masatoshi started his career at McKinsey & Company, covering the healthcare and high-tech practice. He co-founded GRA&GREEN Inc., a sustainability biotechnology company with researchers in 2017. After graduate studies at Columbia University in Electrical and Computer Engineering, he became a specially-appointed Associate Professor at Kyoto University in 2022. Based in New York, he has been responsible in the strategy of several technology startups. He has been named in Forbes Asia 30 Under 30 in 2018, and recognized in other international awards. Besides his roles, he served as special advisor and researcher to the Governors of Osaka and Tokyo in 2016, and a junior council of American Museum of Natural History from 2022.

After graduating from the Faculty of Agriculture, Meiji University, he has been worked mainly in China for about 7 years at Nihon Nohyaku Co., Ltd. After that, working for a major management consulting company, he started FOODBOX Co., Ltd. in 2019. FOODBOX provide consulting specialized in the food and agriculture fields to companies, local governments, and professional farmers. He is working to establish a new position as a FOOD CATALYST, "connecting between the food and agriculture industry and different industries," and also focusing on producing young human resources.

26 years' experience in IPO operations and start-up support at SMBC Nikko Securities. Became the youngest person ever to be appointed Head of the Third Corporate Clients Department at the head office. Involved in a variety of deals, including university-launched ventures, very large companies, and investment fund deals. Most recently, he was in charge of identifying venture companies at Sumitomo Mitsui Banking Corporation and SMBC Nikko Securities, where he scrutinised a cumulative total of 500 companies per year, or more than 2,000 companies in four years.